Subscribe To
Esperion therapeutics: speculative buy, playing the $300 million milestone litigation
Esperion reported Q2 bempedoic acid revenue of $20.3M; we expect the...
August 29, 2023, 8:46 am
Esperion presents two clear outcomes study late-breakers at european society of cardiology congress 2023
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% r...
August 26, 2023, 3:00 pm
Esperion announces submission of application for expanded indication with the european medicines agency (ema) for nilemdo® (bempedoic acid) tablet and nustendi® (bempedoic acid and ezetimibe) tablet
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich...
June 28, 2023, 12:00 pm
Esperion presents results from clear outcomes primary prevention analysis at 83rd american diabetes association scientific sessions
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary...
June 24, 2023, 6:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm